ReviewJournal of the National Cancer Institute2021
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker.
Review in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials.European journal of cancer (Oxford, England : 1990) · 2023Pooled it
- CYLD Mutations, PD-L1 and HPV; A Pan-Cancer Landscape Analysis.Research square · 2026Article
- T cell adaptation in chronic infections and tumors.Cellular & molecular immunology · 2026Review
- Case Report: Complete response to the concurrent neoadjuvant radiation therapy and pembrolizumab in a locally recurrent, chemotherapy-refractory undifferentiated pleomorphic sarcoma of bone.Frontiers in oncology · 2026Article
- Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Review
- PD-L1 Expression is Mediated by microRNA Processing, Wnt/β-Catenin Signaling, and Chemotherapy in Wilms Tumor.Pediatric blood & cancer · 2025Article
- Overcoming immunotherapy resistance in non-small cell lung cancer: a narrative review of related factors.Immunotherapy · 2025Review
- Molecular and Pathological Heterogeneity of Synchronous Small and Large Duct Intrahepatic Cholangiocarcinoma-A Case Series.Current oncology (Toronto, Ont.) · 2025Article
- Review
- PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome.NPJ genomic medicine · 2025Article
- Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies.Frontiers in immunology · 2025Review
- Tumor necrosis factor superfamily signaling: life and death in cancer.Cancer metastasis reviews · 2024Review
- MDM2 inhibitors in cancer immunotherapy: Current status and perspective.Genes & diseases · 2024Review
- RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation.Oncogene · 2024Article
- Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines.Pharmaceutics · 2023Article
- Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.Cancer immunology, immunotherapy : CII · 2023Article
- An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.European journal of medical research · 2023Article
- Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.Communications medicine · 2023Article
- Review
- Evaluation of immunotherapy efficacy in gynecologic cancer.Frontiers in immunology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
The development of checkpoint blockade immunotherapy has transformed the medical oncology armamentarium. But despite its favorable impact on clinical outcomes, immunotherapy benefits only a subset of patients, and a substantial proportion of these individuals eventually manifest resistance. Serious immune-related adverse events and hyperprogression have also been reported. It is therefore essential to understand the molecular mechanisms and identify the drivers of therapeutic response and resistance. In this review, we provide an overview of the current and emerging clinically relevant genomic biomarkers implicated in checkpoint blockade outcome. US Food and Drug Administration-approved molecular biomarkers of immunotherapy response include mismatch repair deficiency and/or microsatelliteinstability and tumor mutational burden of at least 10 mutations/megabase. Investigational genomic-associated biomarkers for immunotherapy response include alterations of the following genes/associated pathways: chromatin remodeling (ARID1A, PBRM1, SMARCA4, SMARCB1, BAP1), major histocompatibility complex, specific (eg, ultraviolet, APOBEC) mutational signatures, T-cell receptor repertoire, PDL1, POLE/POLD1, and neo-antigens produced by the mutanome, those potentially associated with resistance include β2-microglobulin, EGFR, Keap1, JAK1/JAK2/interferon-gamma signaling, MDM2, PTEN, STK11, and Wnt/Beta-catenin pathway alterations. Prospective clinical trials are needed to assess the role of a composite of these biomarkers to optimize the implementation of precision immunotherapy in patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.